Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Schizophrenia, Alcohol Use Disorder
Interventions: Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 58
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 36
States / cities: Little Rock, Arkansas • Sacramento, California • Whittier, California + 31 more

Conditions: Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions: Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy; Drug · Behavioral
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Cough Reflex Sensitivity
Interventions: diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Osteoarthritis of the Hand
Interventions: AMPION™, Saline; Biological
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Radiculopathy
Interventions: Lenalidomide (CC-5013); Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 23
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 20 more

Conditions: Healthy
Interventions: LY2541546 - IV, LY2541546 - SC, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Evansville, Indiana • Indianapolis, Indiana

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Conditions: Hypogammaglobulinemia, Lung Transplantation
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Disease
Interventions: NR2B NMDA Antagonist CP-101,606 (traxoprodil); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Peripheral Arterial Disease, Intermittent Claudication
Interventions: Zibotentan (ZD4054), placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo; Radiation · Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder, Bipolar Depression, Manic Depression
Interventions: Uridine, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 13 Years to 21 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ischemia-Reperfusion Injury
Interventions: nitric oxide for inhalation, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Methamphetamine Dependence
Interventions: Bupropion, Placebo; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: Obstructive Sleep Apnea
Interventions: Acetazolamide, Placebo, Continuous Positive Airway Pressure; Drug · Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Immunoglobulin A Nephropathy, IgAN
Interventions: Ravulizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 39
States / cities: Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more

Conditions: Cytomegalovirus Infection
Interventions: Placebo, Valganciclovir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 30 Days
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more

Conditions: Aggression, Anger, Emotion Regulation, Self-Control, Stress
Interventions: HBMT, Other Training; Behavioral
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Healthy Adults
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Allergic Rhinitis
Interventions: Grass pollen extract, Placebo injection; Biological · Other
Lead sponsor: Amber Patterson; Other
Eligibility: 15 Years to 24 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
Interventions: Naltrexone, Modafinil, Placebo; Drug
Lead sponsor: Kyle Kampman; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Healthy Subjects, Cardiac Repolarization
Interventions: Placebo, ASP1941, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Medication and Counseling for Controlled Drinking (Project SMART)

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

A Study of LY2541546 in Healthy Postmenopausal Women

Atrasentan in Patients With IgA Nephropathy

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

Hostile Bias Modification Training Online Study II

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Safety of Lymph Node Injection for Allergen Immunotherapy

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects